Decoration of Outer Membrane Vesicles with Multiple Antigens by Using an Autotransporter Approach

Maria Daleke-Schermerhorn, Tristan Felix, Zora Soprova, Corinne ten Hagen-Jongman, Vikström David, Laleh Majlessi, Beskers Joep, Frank Follmann, Karin de Punder, Nicole van der Wel, et al.

To cite this version:


HAL Id: pasteur-01144249

https://hal-pasteur.archives-ouvertes.fr/pasteur-01144249

Submitted on 21 Apr 2015

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

Copyright
Decoration of Outer Membrane Vesicles with Multiple Antigens by Using an Autotransporter Approach

Maria H. Daleke-Schermerhorn,a,b Tristan Felix,c,d Zora Sopova,a Corinne M. ten Hagen-Jongman,a,b David Vikström,a,f Laleh Majlessi,a,e,e,1 Joep Beskens,a Frank Hollmann,b Karin de Punder,b,e,e Nicole N. van der Wel,e,e Thomas Baumgarten,a,e Thang V. Pham,b Sander R. Piersma,b1 Connie R. Jiménez,b Peter van Ulsen,b Jan-Willem de Gier,a Claude Leclerc,c,d Wouter S. P. Jong,b ab Joen Luirinkab

Section Molecular Microbiology, Department of Molecular Cell Biology, Faculty of Earth and Life Sciences, VU University, Amsterdam, The Netherlands; a,ab Aker BioScience AB, Stockholm, Sweden; ab Institut Pasteur, Unité de Régulation Immunitaire et Vaccinologie, Paris, France; ab INSERM, U1041, Paris, France; b,ab Center for Biomembrane Research, Department of Biochemistry and Biophysics, Stockholm University, Stockholm, Sweden; ab Xbrane Bioscience AB, Stockholm, Sweden; ab Chlamydia Vaccine Research; ab Department of Infectious Disease Immunology, Statens Serum Institut, Copenhagen, Denmark; ab The Netherlands Cancer Institute, Antonie van Leeuwenhoek Hospital, Amsterdam, The Netherlands; ab Department of Medical Oncology, OncoProteomics Laboratory, VU University Medical Center, Amsterdam, The Netherlands.

Outer membrane vesicles (OMVs) are spherical nanoparticles that naturally shed from Gram-negative bacteria. They are rich in immunostimulatory proteins and lipopolysaccharide but do not replicate, which increases their safety profile and renders them attractive vaccine vectors. By packaging foreign polypeptides in OMVs, specific immune responses can be raised toward heterologous antigens in the context of an intrinsic adjuvant. Antigens exposed at the vesicle surface have been suggested to elicit protection superior to that from antigens concealed inside OMVs, but hitherto robust methods for targeting heterologous proteins to the OMV surface have been lacking. We have exploited our previously developed hemoglobin protease (Hbp) autotransporter platform for display of heterologous polypeptides at the OMV surface. One, two, or three of the Mycobacterium tuberculosis antigens ESAT6, Ag85B, and Rv2660c were targeted to the surface of Escherichia coli OMVs upon fusion to Hbp. Furthermore, a hypervesculating ΔtolR ΔtolA derivative of attenuated Salmonella enterica serovar Typhimurium SL3261 was generated, enabling efficient release and purification of OMVs decorated with multiple heterologous antigens, exemplified by the M. tuberculosis antigens and epitopes from Chlamydia trachomatis major outer membrane protein (MOMP). Also, we showed that delivery of Salmonella OMVs displaying Ag85B to antigen-presenting cells in vitro results in processing and presentation of an epitope that is functionally recognized by Ag85B-specific T cell hybridomas. In conclusion, the Hbp platform mediates efficient display of (multiple) heterologous antigens, individually or combined within one molecule, at the surface of OMVs. Detection of antigen-specific immune responses upon vesicle-mediated delivery demonstrated the potential of our system for vaccine development.

Gram-negative bacteria naturally release 20- to 250-nm spherical, bilayered structures known as outer membrane vesicles (OMVs) from their surfaces (1). These OMVs are formed by bulging and pinching off a portion of the outer membrane (OM) and consequently contain lipopolysaccharide (LPS), phospholipids, and the major outer membrane proteins (OMPs) typically found in the Gram-negative OM (2, 3). However, the protein composition of OMVs differs slightly from that of the OM as some proteins are enriched in the vesicles while others are excluded (2, 4–6). OMVs also contain soluble periplasmic components, which become entrapped in the lumen during vesiculation, but very little inner membrane (IM) and cytoplasmic material (2, 4). OMVs have been detected under a variety of culture conditions and natural environments (1) and in infected blood and host tissue (7, 8), and they are believed to play important roles in bacterial growth, survival (9, 10), and virulence (8, 11, 12).

OMVs are loaded with LPS and immunogenic proteins, which allow them to stimulate the innate immune system and simultaneously trigger antigen-specific humoral and CD4+ T cell responses (13). Furthermore, OMVs can be produced in large amounts using hypervesculating strains that carry genetic mutations affecting certain cell envelope proteins, most notably in the tol-pal system (14), and they are easily separated from their parent bacteria by filtration and differential centrifugation methods (15). These properties make OMVs attractive as vaccines. Importantly, mice immunized with OMVs are protected against challenge with virulent bacteria (13, 16, 17), and OMV vaccines against Neisseria meningitidis serogroup B (MenB) have been shown to offer protection and are routinely and safely administered to humans in vaccine programs (18).

Several recent studies have shown that heterologous proteins can be targeted to OMVs upon production in the OM or periplasm (19, 20) or as translational fusions to vesicle-associated proteins (21, 22), opening up the interesting possibility of equipping OMVs with an engineered antigen repertoire. An increasing body of evidence suggests that extracellular antigens evoke im-

Received 12 June 2014 Accepted 10 July 2014 Published ahead of print 18 July 2014

Editor: H. L. Drake

Address correspondence to Maria H. Daleke-Schermerhorn, maria.daleke@aberabio.com, or Joen Luirink, s.luirink@vu.nl.

* Present address: Laleh Majlessi, UP Pathogénomique Mycobactérienne Intégrée, Institut Pasteur, Paris, France; Karin de Punder, Institute for Medical Psychology, Charité Universitätsmedizin, Berlin, Germany; Nicole N. van der Wel, Department of Cell Biology and Histology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.

Copyright © 2014, American Society for Microbiology. All Rights Reserved. doi:10.1128/AEM.01941-14
mune responses superior to those of intracellular antigens (23–25). Recently, antibody responses to a heterologous antigen packed into the lumen of *Salmonella* OMVs were observed to be lower than to those endogenous vesicle OMPs and LPS (20), suggesting that surface-exposed antigens may elicit superior immune responses also in vesicles.

We recently engineered the *Escherichia coli* autotransporter (AT) hemoglobin protease (Hbp) into a platform for high-density surface display of heterologous proteins in Gram-negative bacteria (26). The AT pathway is one of the mechanisms that have evolved in Gram-negative bacteria to transfer proteins across their complicated cell envelopes, and it is used for secretion of large virulence factors (27). ATs comprise three domains: an N-terminal signal peptide that mediates translocation across the IM, a central passenger domain that forms the functional part of the protein, and a C-terminal β-domain that inserts into the OM and facilitates translocation of the passenger to the bacterial surface or medium (27). Because ATs combine a relatively simple secretion mechanism with a flexible transport capacity, they have attracted attention as carriers for transport of heterologous proteins to the extracellular milieu (28, 29). For this purpose, heterologous sequences have often been fused directly to the C-terminal β-domain or to the N terminus of the passenger domain (27, 30, 31). We took a slightly different approach, capitalizing on the crystal structure of the Hbp passenger. The mature Hbp passenger folds into an ~100-Å β-helical stem structure that functions as a stable scaffold for five protruding side domains (d1 to d5) (32). We showed that these side domains are dispensable for translocation and that they can be replaced by heterologous polypeptides (26). In combination with a mutation in the β-domain that prevents release of the passenger domain (Fig. 1A) (33–35), optimal expression of heterologous proteins can be achieved at some distance from the cell surface (26).

Here, we show, as exemplified by well-known antigens from *Mycobacterium tuberculosis*, that the Hbp platform can be used to achieve high-density exposure of multiple full-length heterologous antigens at the surface of both *E. coli* and *Salmonella* OMVs, with minimal perturbation of the natural OMV protein composition. Importantly, we show that *M. tuberculosis* antigens displayed at the surface of *Salmonella* OMVs are processed and presented by antigen-presenting cells in a manner resembling the situation during natural mycobacterial infection. Furthermore, two B and T cell epitope-containing internal fragments of the *Chlamydia trachomatis* major outer membrane protein (MOMP) were efficiently displayed at the surface of *Salmonella* OMVs. This demonstrated that the Hbp platform can be used for expression of antigenically important polypeptides that are difficult to produce recombinantly in native full-length form. Collectively, the data demonstrate the potential of our approach for OMV vaccine development.

**MATERIALS AND METHODS**

**Bacterial strains and growth conditions.** *E. coli* strain JC8031 (∆tolRA) (36), *Salmonella enterica serovar Typhimurium* SL2361 (37), and the isogenic SL3261 (∆tolRA) mutant strain constructed in this study were grown at 37°C in LB medium containing 0.2% glucose. When appropriate, kanamycin was used at a concentration of 50 μg/ml (*E. coli*) or 25 μg/ml (S. Typhimurium), and chloramphenicol was used at a concentration of 30 μg/ml.

**Plasmids.** Open reading frames (ORFs) encoding Hbp (derivatives) were expressed under the control of a lacUV5 promoter from pEH3 (38) plasmids. All plasmids were based on pEH3-HbpD(ΔBamHI) (34), in which the sequence encoding the passenger–β-domain junction has been altered to prevent autocatalytic intradomain cleavage. For expression of Hbp lacking side domain d1, we made use of a previously described derivative of pEH3-HbpD(ΔBamHI), pHbp(Δd1) (26), in which the sequence encoding d1 has been substituted for GlySer-encoding linker sequences containing ScaI and BamHI restriction sites. HbpD-ESAT6, a chimera in which d1 of Hbp was replaced by the *M. tuberculosis* antigen ESAT6, was expressed from plasmid pHbpD(Δd1)-ESAT6 (26). In this plasmid, a ScaI/BamHI-flanked *E. coli* codon-optimized fragment corresponding to *M. tuberculosis* esxA was inserted into the ScaI and BamHI sites of pHbpD(Δd1). Two additional plasmids, pHbpD-Ag85BNCESAT6 and pHbpD-Ag85BNC+ESAT6-Rv2660c (W. S. P. Jong, M. H. Daleke-Schermerhorn, and J. Luirink, unpublished data), were used for expression of HbpD-Ag85BNCESAT6 and HbpD-Ag85BNC+ESAT6-Rv2660c. In the *hbp* ORFs of these plasmids, the sequences encoding d1, d2, d4, and d5 had been substituted for GlySer-encoding linker sequences containing ScaI and BamHI restriction sites. Subsequently, ScaI/BamHI-flanked PCR fragments of *M. tuberculosis* H37Rv fbpA encoding an N-terminal (Ag85BNC, amino acids [aa] 1 to 126) and a C-terminal (Ag85BNC, aa 118 to 285) portion of Ag85B were inserted into the positions corresponding to d2 and d1, respectively, while the above-mentioned esxA fragment replaced the d4-encoding sequence. In pHbpD-Ag85BNCESAT6-Rv2660c, a PCR fragment of *M. tuberculosis* H37Rv Rv2660c additionally replaced the sequence coding for d5. For expression of HbpD-MOMPIV-MOMPII, a chimera in which domains d1 and d2 of the Hbp passenger were replaced by GlySer-flanked sequences corresponding to residues 266 to 350 (MOMPIV) and 155 to 190 (MOMPII) of *Chlamydia trachomatis* D/UW-3/CX MOMP, plasmid pHbpD-MOMPIV-MOMPII was used (Jong et al., unpublished). In this plasmid, *E. coli* codon-optimized synthetic DNA fragments encoding the two MOMP sequences were inserted into the *hbp* ORF using ScaI/BamHI restriction sites.

**Construction of a ΔtolRA mutant in *S. Typhimurium***. *S. Typhimurium* SL3261 ΔtolRA was constructed using the λ Red-mediated recombination system essentially as described by Datsenko and Wanner (39). Briefly, primers tolRASLHP1 (5'–TGG ACC GGC AGG CGT TTA CCG TAA GGC AAA ACA AGG AGG GTG TTA CCA TGA TCC CCG GGA TCC GTC GAC C-3') and tolRASLHP2 (5'–ACT GCT CTA ACT TCC ATA AAG AAA AGT ATC TAC AGT TTA AAG CTT ACT GTG TTT GTG GTC GGC TGG AGC TTC GTC G-3') were used to amplify the tolRA gene using PCR. The PCR product was electroporated into *S. Typhimurium* carrying the Red helper plasmid pKD46, allowing replacement of the tolRA genes with the gene behind a *Red*-mediated recombination. The resulting strain was cured from the temperature-sensitive pKD46 by cultivation at 37°C. Insertion of the kanamycin cassette PCR product with suitable overhangs for recombination into the chromosome of SL3261. The PCR product was electroporated into *S. Typhimurium* carrying the Red helper plasmid pKD46, allowing replacement of the tolRA genes with the gene behind a *Red*-mediated recombination. The resulting strain was cured from the temperature-sensitive pKD46 by cultivation at 37°C. Insertion of the kanamycin cassette into the correct position on the chromosome was verified essentially as described by Baba and Mori (40) using the primers TolRAl (5’–CGT AAC AAG CAA ACA CAA GGG G-3’) and TolRAd (5’–CAG CCA GGA CCA GTA ACA AC-3’).

**General protein production and analysis.** The expression of ORFs encoding Hbp derivatives from pEH3 plasmids (38) was under the control of the lacUV5 promoter. Strains harboring pEH3 vectors were grown until an optical density at 660 nm (OD<sub>600</sub>) of ~0.3 (*E. coli*) or ~0.6 (*S. Typhimurium*), at which time expression of Hbp derivatives was induced in the presence of 50 μM or 1 mM isopropyl β-D-thiogalactopyranoside (IPTG) for 3 h for *E. coli* or of 50 or 100 μM IPTG for 1 h for *S. Typhimurium*. Bacteria were separated from spent medium by low-speed centrifugation, after which culture supernatants were treated with trichloroacetic acid to precipitate proteins or used to isolate OMVs as described below. Proteins were analyzed by SDS-PAGE, followed by staining with Coomassie G-250 (Bio-Rad) or immunoblotting. Immunostaining was performed with mouse monoclonal antibodies directed against ESAT6 (Hyb 76-8) (41), Ag85B (TD17) (42), or RNA polymerase (W0003; NeoClone) or with rabbit polyclonal serum recognizing the Hbp passenger domain (140).
FIG 1 Hbp derivatives used for display at the OMV surface. (A) Wild-type Hbp (included for reference) is composed of three domains: (i) an N-terminal cleavable signal sequence (ss), (ii) a secreted passenger domain, and (iii) a C-terminal β-domain that becomes integrated into the OM. Side domains d1 to d5 and the autochaperone domain (ac) that is involved in OM translocation of the passenger domain are indicated, while the remainder of the passenger domain is black. The mutation that prevents autocatalytic intradomain cleavage and concomitant release of the passenger, resulting in a surface-exposed (display) version of Hbp, is marked X. Numbers above the diagrams correspond to the amino acid positions in wild-type Hbp. Insertion of a 9- to 11-aa flexible linker (FL) comprising Gly and Ser residues and insertions of the mycobacterial antigens ESAT6 (E–6), an N-terminal fragment (aa 1 to 126; 85N) and a C-terminal fragment of Ag85B, Rv2660c (26), and the internal fragments MOMPIP (aa 266 to 350; IV) and MOMPII (aa 155 to 190; II) of C. trachomatis MOMP are indicated. All inserts are flanked by short Gly/Ser linkers. (B) Schematic representation of Hbp-mediated antigen display on OMVs, exemplified by HbpD-Ag85B-N-ESAT6-Rv2660c. Ag85B, split into N-terminal and C-terminal fragments, ESAT6, and Rv2660c are fused to the Hbp passenger by replacement of side domains d2, d1, d4, and d5, respectively. Upon production in hypervesiculating E. coli or Salmonella strains, the Hbp chimera, which localizes in the bacterial outer membrane (OM), becomes incorporated in and displayed at the surface of the newly formed outer membrane vesicles (OMV). IM, inner membrane. The figure was made using Servier Medical Art and the crystal structures of the Hbp passenger (blue) and β-domain (red) (32, 66).

(43), the Hbp β-barrel (SN477) (44), C. trachomatis serovar D MOMP (I. Rosenkrands, Statens Serum Institut, Denmark), DnaJ (45), BamA (J. Tommassen, Utrecht University, The Netherlands), SurA (T. Silhavy, Princeton University, USA), Skp (46), leader peptidase (Lep), OmpA, SecG, or trigger factor (TF) (from our own laboratory collection), or with rat antisera specific for Rv2660c (P. Andersen, Statens Serum Institut, Denmark). For quantitative Western blotting, secondary IRDye 680RD goat anti-rabbit IgGs (Li-Cor) were used, and fluorescent signals were detected with an Odyssey Infrared Imaging System (Li-Cor).

**OMV isolation.** Culture supernatants obtained by low-speed centrifugation were passed through 0.45-μm-pore-size filters (Millipore) and centrifuged at 208,000 × g for 60 min to separate OMVs from soluble proteins. The pelleted crude vesicles were resuspended in phosphate-buffered saline (PBS).

Velocity density gradient centrifugation was performed essentially as described previously (15). Briefly, the crude vesicle preparation was adjusted to 45% (vol/vol) OptiPrep density gradient medium (Axis Shield) in 400 μl and transferred to the bottom of a 12.5-ml ultracentrifuge tube. Subsequently, OptiPrep-PBS dilutions of 35% (3 ml), 30% (3 ml), 25% (2 ml), 20% (2 ml), 15% (1 ml), and 10% (1 ml) were layered in descending order atop the preceding layers. Gradients were centrifuged at 130,000 × g for 16 h, and fractions of equal volumes were collected sequentially from the top.

**Proteinase K accessibility assay.** OMVs were resuspended in a buffer containing 50 mM Tris-HCl (pH 7.4) and 1 mM CaCl₂. When required, OMVs were lysed by incubation with 0.5% (vol/vol) Triton X-100 (Sigma-Aldrich) for 15 min on ice. Intact and lysed OMVs were incubated for 30 min at 37°C in the presence of 100 μg/ml proteinase K (Roche Applied Biologicals).
Science). The reaction was stopped by the addition of 0.1 mM phenylmethylsulfonyl fluoride (Roche Applied Science), and all samples were precipitated with trichloroacetic acid.

**Immunogold EM.** Crude OMVs in PBS were fixed by addition of an equal volume of fixation solution (4% paraformaldehyde and 0.2% glutaraldehyde in 0.4 M PHEM buffer consisting of 240 mM PIPES [piperazine-N,N′-bis(2-ethanesulfonic acid)], 100 mM HEPES, 8 mM MgCl₂, and 40 mM EGTA, pH 6.9) and incubation for 2 h at room temperature. The fixed OMVs were pelleted by centrifugation at 280,000 × g for 20 min, after which they were resuspended in 0.1 M PHEM buffer containing 0.5% paraformaldehyde. Samples were transferred to a Formvar-coated copper grid, and immunolabeling was performed using antisera recognizing the Hbp passenger (J40) (43), rabbit anti-mouse bridging serum and copper grid, and immunolabeling was performed using antiserum recognizing the Hbp passenger (J40) (43), rabbit anti-mouse bridging serum and subsequent electron microscopy (EM) analysis was carried out using a CM 10 microscope (FEI).

**Dynamic light scattering.** The diameters of isolated OMVs were determined by dynamic light scattering using a Zetasizer instrument (Malvern Instruments) as described previously (47). The dynamic light-scattering data were analyzed with the latest Zetasizer family software (version 7.04; Malvern Instruments) using the normal resolution analysis mode. All data met the quality criteria (polydispersity index lower than 0.3).

**Mass spectrometric (MS) analysis.** Protein bands were excised from Coomassie-stained SDS-PAGE gels and processed for in-gel digestion. Each gel slice was cut in pieces, washed with water, and destained in 50 mM ammonium bicarbonate (ABC)—50% (vol/vol) methanol. The slices were dehydrated in 50 mM ABC—50% (vol/vol) acetone, followed by 100% acetone, and dried in a vacuum centrifuge. Subsequently, the slices were rehydrated in 50 mM ABC containing 4.8 ng/μl Trypsin Gold (Promega) and 0.01% ProteaseMAX surfactant (Promega) for 1 h at 50°C. The trypsin was inactivated by the addition of 0.5% trifluoroacetic acid, after which the extracted tryptic peptides were dried in a vacuum centrifuge.

For tandem MS (MS/MS) analysis, the extracted peptides were concentration and desalted on C₁₈ ZipTips (Millipore), eluted in α-cyano-4-hydroxy-cinnamic acid matrix, and analyzed by matrix-assisted laser desorption ionization–two-stage time of light (MALDI-TOF/TOF) MS (ABI ScieX TOF/TOF 5800). An MS/MS spectrum search was performed against the E. coli K-12 MG1655 database using Mascot software (Matrix Science), with a peptide mass tolerance of 1.2 Da and a fragment mass tolerance of 0.6 Da and allowing a single site of miscleavage and oxidation of methionine as a variable modification.

For nanoscale liquid chromatography coupled to tandem mass spectrometry (nano-LC-MS/MS), the tryptic peptides were resuspended in 0.1% acetic acid, separated on a capillary C₁₈ ZipTips (Millipore), eluted in α-cyano-4-hydroxy-cinnamic acid matrix, and analyzed by matrix-assisted laser desorption ionization–two-stage time of flight (MALDI-TOF/TOF) MS (ABI ScieX TOF/TOF 5800). An MS/MS spectrum search was performed against the E. coli K-12 MG1655 database using Mascot software (Matrix Science), with a peptide mass tolerance of 1.2 Da and a fragment mass tolerance of 0.6 Da and allowing a single site of miscleavage and oxidation of methionine as a variable modification.

**RESULTS**

Hbp platform allows targeting of heterologous proteins to E. coli OMVs. We have recently shown that heterologous proteins can be efficiently displayed at the surface of E. coli and S. Typhi-murium as fusion partners of the AT Hbp (26, 34), and we reasoned that Hbp might also be used to target proteins to OMVs (Fig. 1B). First, to establish that Hbp itself is targeted to OMVs, an ORF encoding an uncleaved (display) version of Hbp (Fig. 1A) that lacks side domain d1 (HbpD-Δd1) was expressed under the control of a lac-derived promoter in the hypervesculating E. coli strain JC8031 (ΔtolRA) (36) in the presence of 50 μM IPTG. OMVs were separated from soluble secreted proteins in cell-free supernatants by ultracentrifugation, and the production of Hbp was monitored by SDS-PAGE and Coomassie staining. Successful enrichment of OMVs in the high-speed centrifugation pellet was confirmed by the presence of two bands of ~35 and ~32 kDa, which were verified by mass spectrometry (data not shown) to correspond to the major OMPS and OMV marker proteins OmpF/C and OmpA (4, 5) (Fig. 2A, lanes 16 to 20). As expected, HbpD-Δd1 accumulated as an ~116-kDa band in the whole-cell fraction (Fig. 2A, lane 2). Interestingly, in the culture supernatant a band of similar size was detected (Fig. 2A, lane 7), which in similarity to the porins was detected in the OMV fraction after ultracentrifugation (Fig. 2A, lane 17, and B, lane 2). Furthermore, upon velocity density gradient centrifugation of the crude vesicles, HbpD-Δd1 migrated to the same fractions as OmpA, -F, and -C (Fig. 2C). This confirms that the Hbp display variant is tightly associated and most likely integral to the OMVs. Of note, comparison of the ratios of Hbp and OmpA in OMVs and whole cells by quantitative Western blotting indicated that Hbp is neither enriched nor selectively excluded in the OMVs (not shown).

To investigate whether Hbp can target heterologous proteins to OMVs, three chimeric constructs containing one, two, or three M. tuberculosis antigens simultaneously (26; also Jong et al., unpublished) (Fig. 1) were produced in JC8031, and crude OMVs were isolated. In the first chimera, HbpD-ESAT6, d1 was replaced by the 9.9-kDa antigen ESAT6 (26). In the second chimera, HbpD-Ag85B-C₅₃-N-ESAT6, two fragments corresponding to the N-terminal (residues 1 to 126) and the C-terminal (residues 118 to 285) portions of the mature 31-kDa protein Ag85B replaced d2 and d1, respectively, and ESAT6 was fused to the position corresponding to d4. In the third chimera, HbpD-Ag85B-C₅₃-N-ESAT6-Rv2660c, the full-length 7.6-kDa Rv2660c protein was additionally inserted via substitution of d5 (Jong et al., unpublished). Importantly, all three chimeras were detected in the OMV fraction upon protein staining (Fig. 2A) and by immunoblotting (Fig. 2B).

Furthermore, HbpD-ESAT6 was shown to migrate to the same fractions as OmpF/C and OmpA upon velocity density gradient centrifugation, verifying its presence in the OMVs (Fig. 2D). A minor band migrating just below the ~126-kDa full-length HbpD-ESAT6 chimera was also detected (Fig. 2A, lane 18, and 2B, lane 3), which represents a previously observed product that probably results from proteolytic cleavage of the passenger (26). Of
note, the levels of OMV production appeared to be slightly affected upon expression of the two most complex Hbp chimeras, as judged by the levels of the porins OmpF/C and OmpA (Fig. 2A, lanes 19 to 20, and 2B, lanes 4 to 5). Nevertheless, together the results show that the Hbp platform allows efficient targeting of multiple heterologous proteins simultaneously to E. coli OMVs.

**Hbp-antigen fusions are displayed at the surface of E. coli OMVs.** Hbp naturally undergoes an autocatalytic cleavage mechanism after translocation across the OM, resulting in release of the passenger from the αβ-domain (33,35). We previously created an uncleaved version of Hbp by mutating the intradomain cleavage site, in which the exported passenger remains covalently attached to the αβ-domain and is exposed at the bacterial surface (34). To determine if Hbp is exposed at the OMV surface as well, the localization of HbpD-Δd1 was analyzed by immunogold labeling and EM. OMVs from E. coli JC8031 producing HbpD-Δd1, HbpD-ESAT6, HbpD-Ag85Bc-N-ESAT6, and HbpD-Ag85Bc-N-ESAT6-Rv2660c in the presence of 50 μM IPTG or harboring the empty vector (EV). Hbp proteins (chimeras) are marked by asterisks, and arrowheads indicate the bands corresponding to PDH-E1, GroEL, OmpF/C, and OmpA. (A) SDS-PAGE/Coomassie analysis of fractions containing an equivalent of 0.1 OD₆₆₀ unit of cells, culture medium, secreted soluble proteins (medium 2), and 3 OD₆₆₀ units of crude OMVs from E. coli JC8031 expressing HbpD-Δd1, HbpD-ESAT6, HbpD-Ag85Bc-N-ESAT6, and HbpD-Ag85Bc-N-ESAT6-Rv2660c in the presence of 50 μM IPTG or harboring the empty vector (EV). Hbp proteins (chimeras) are marked by asterisks, and arrowheads indicate the bands corresponding to PDH-E1, GroEL, OmpF/C, and OmpA. (B) The OMV samples from panel A were analyzed by immunoblotting using antibodies recognizing the β-domain of Hbp (αβ-dom), ESAT6, Ag85B, Rv2660c, and OmpA. (C and D) SDS-PAGE/Coomassie analysis of equal volumes of all fractions obtained after velocity density gradient centrifugation of crude OMVs containing HbpD-Δd1(C) or HbpD-ESAT6 (D). The concentration of OptiPrep (%) and bands corresponding to HbpD-Δd1, HbpD-ESAT6, PDH-E1, GroEL, OmpF/C, and OmpA are indicated. α, anti.

**FIG 2** Targeting of (multiple) heterologous proteins to E. coli OMVs by fusion to the passenger of Hbp. (A) SDS-PAGE/Coomassie analysis of fractions containing an equivalent of 0.1 OD₆₆₀ unit of cells, culture medium, secreted soluble proteins (medium 2), and 3 OD₆₆₀ units of crude OMVs from E. coli JC8031 expressing HbpD-Δd1, HbpD-ESAT6, HbpD-Ag85Bc-N-ESAT6, and HbpD-Ag85Bc-N-ESAT6-Rv2660c in the presence of 50 μM IPTG or harboring the empty vector (EV). Hbp proteins (chimeras) are marked by asterisks, and arrowheads indicate the bands corresponding to PDH-E1, GroEL, OmpF/C, and OmpA. (B) The OMV samples from panel A were analyzed by immunoblotting using antibodies recognizing the β-domain of Hbp (αβ-dom), ESAT6, Ag85B, Rv2660c, and OmpA. (C and D) SDS-PAGE/Coomassie analysis of equal volumes of all fractions obtained after velocity density gradient centrifugation of crude OMVs containing HbpD-Δd1(C) or HbpD-ESAT6 (D). The concentration of OptiPrep (%) and bands corresponding to HbpD-Δd1, HbpD-ESAT6, PDH-E1, GroEL, OmpF/C, and OmpA are indicated. α, anti.
brane proteins OmpF/C were also susceptible to proteinase K treatment (Fig. 4A), which is likely because the loops in these β-barrel proteins are (partly) exposed at the surface of the E. coli OMVs.

Taken together, the results show that Hbp can be used to efficiently decorate the surface of E. coli OMVs with antigens, without altering the size, shape, or orientation of the OMVs.

**Effect of Hbp expression on OMV protein composition.** Although OmpF/C, OmpA, and Hbp (chimeras) were the most abundant proteins, we noticed that our OMV preparations contained two additional bands of ~60 and ~90 kDa upon expression of Hbp (derivatives) (Fig. 2A). These bands became more prominent upon higher levels of Hbp expression (Fig. 4B) shows results of induction with 1 mM IPTG). The two bands were determined by mass spectrometry to correspond to the cytoplasmic proteins GroEL and pyruvate dehydrogenase E1 (PDH-E1) (data not shown). Importantly, immunoblotting showed that our OMVs contained the periplasmic proteins SurA and Skp but not the IM proteins SecG and Lep nor the cytoplasmic proteins TF, DnaJ, and RNA polymerase (Fig. 4C). Therefore, we could rule out that the presence of GroEL and PDH-E1 in our OMVs was a result of generic contamination with cytoplasmic material. Furthermore, GroEL and PDH-E1 are not integrated in the vesicles but probably loosely associated with the OMV surface since they were both degraded upon treatment of intact OMVs with proteinase K (Fig. 4B). In addition, GroEL and, to some extent, also
TABLE 1 Proteins downregulated in E. coli OMVs upon production of Hbp-Δd1 or HbpD-ESAT6

<table>
<thead>
<tr>
<th>UniProt accession no.</th>
<th>Gene name</th>
<th>Description</th>
<th>Spectral count</th>
<th>Expression in OMVs containing:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>HbpD-Δd1</td>
<td>HbpD-ESAT6</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>EV</td>
<td>Δd1</td>
</tr>
<tr>
<td>P07024</td>
<td>ushA</td>
<td>Protein UshA</td>
<td>61</td>
<td>6</td>
</tr>
<tr>
<td>P09394</td>
<td>glyQ</td>
<td>Glycrophosphoryl diester phosphodiesterase</td>
<td>41</td>
<td>5</td>
</tr>
<tr>
<td>P05458</td>
<td>ptaA</td>
<td>Protease 3</td>
<td>108</td>
<td>4</td>
</tr>
<tr>
<td>P33363</td>
<td>bgIX</td>
<td>Periplasmic beta-glucosidase</td>
<td>83</td>
<td>10</td>
</tr>
<tr>
<td>P23847</td>
<td>dppA</td>
<td>Periplasmic dipeptide transport protein</td>
<td>60</td>
<td>90</td>
</tr>
<tr>
<td>P06056</td>
<td>groEL</td>
<td>60-kDa chaperonin</td>
<td>57</td>
<td>7</td>
</tr>
<tr>
<td>P08331</td>
<td>cspB</td>
<td>2,3-Cyclic nucleotide 2-phosphodiesterase/3-nucleotidase</td>
<td>71</td>
<td>5</td>
</tr>
<tr>
<td>P45523</td>
<td>fkpA</td>
<td>FKR-type peptidyl-prolyl cis-trans isomerase FkpA&lt;sup&gt;b&lt;/sup&gt;</td>
<td>29</td>
<td>20</td>
</tr>
<tr>
<td>P0AD56</td>
<td>yggE</td>
<td>Uncharacterized protein YggE</td>
<td>27</td>
<td>23</td>
</tr>
<tr>
<td>P31554</td>
<td>lptD</td>
<td>LPS assembly protein LptD</td>
<td>90</td>
<td>39</td>
</tr>
<tr>
<td>P0COV0</td>
<td>degP</td>
<td>Periplasmic serine endoprotease DegP</td>
<td>49</td>
<td>61</td>
</tr>
<tr>
<td>P02930</td>
<td>tolC</td>
<td>Outer membrane protein TolC</td>
<td>54</td>
<td>82</td>
</tr>
<tr>
<td>P45464</td>
<td>lpoA</td>
<td>Penicillin-binding protein activator LpoA</td>
<td>73</td>
<td>86</td>
</tr>
<tr>
<td>P0A855</td>
<td>tolB</td>
<td>Protein TolB</td>
<td>46</td>
<td>71</td>
</tr>
<tr>
<td>P0A940</td>
<td>bama</td>
<td>Outer membrane protein assembly factor Bama</td>
<td>91</td>
<td>140</td>
</tr>
<tr>
<td>P06959</td>
<td>aceF</td>
<td>Dihydrolipoamide residue acetyltransferase component of pyruvate dehydrogenase complex</td>
<td>66</td>
<td>224</td>
</tr>
</tbody>
</table>

<sup>a</sup> Fold change in the OMVs containing either HbpD-Δd1 or HbpD-ESAT6 compared to the empty vector (EV) control OMVs.

<sup>b</sup> FKP, FKS06-binding protein.

PDH-E1 were separated from the porins OmpF/C and OmpA upon velocity density gradient centrifugation (Fig. 2C and D).

To further investigate the influence of the expression of Hbp (derivatives) on the OMV protein composition, OMVs purified by velocity density gradient centrifugation (Fig. 2C and D) were subjected to nano-LC-MS/MS. Of note, because a small number of peptides corresponding to GroEL were (differentially) detected (Table 1), we cannot rule out that the purified OMVs were contaminated with small amounts of nonintegral or lumenal vesicle proteins. Nevertheless, the analysis revealed only minor differences between OMVs containing HbpD-Δd1 or HbpD-ESAT6 and those produced by the strain harboring the empty vector (Tables 1 and 2). Most notably, expression of HbpD-Δd1 or HbpD-ESAT6 led to the incorporation of OsmB, a slight upregulation of OmpX and MipA (Table 2), and downregulation of a limited number of periplasmic and OM proteins, including BglX and DppA, in the OMVs (Table 1). As overexpression of heterologous secretory proteins is known to saturate the Sec machinery capacity, it is possible that this downregulation is the result of competition with overproduced Hbp at the Sec translocon in the IM (51). In conclusion, these results indicate that targeting of Hbp (derivatives) to E. coli OMVs has only a minor effect on the integral and lumenal OMV protein composition.

**Construction of a hypervesiculating S. Typhimurium mutant.** We have recently demonstrated that our Hbp platform can be used to secrete and display heterologous proteins at the surface of the attenuated S. Typhimurium SL3261 vaccine strain (26). Because OMVs offer an interesting alternative to live vaccines, we were interested in generating Salmonella OMVs displaying such antigens. First, to increase the OMV production level, a derivative of S. Typhimurium SL3261 vaccine strain (26). Typhimurium, similar to the hypervesiculating E. coli strain JC8031.

TABLE 2 Proteins upregulated in E. coli OMVs upon production of Hbp-Δd1 or HbpD-ESAT6

<table>
<thead>
<tr>
<th>UniProt accession no.</th>
<th>Gene name</th>
<th>Description</th>
<th>Spectral count</th>
<th>Expression in OMVs containing:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>HbpD-Δd1</td>
<td>HbpD-ESAT6</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>EV</td>
<td>Δd1</td>
</tr>
<tr>
<td>P0ADA7</td>
<td>osmB</td>
<td>Osmotically inducible lipoprotein B</td>
<td>7</td>
<td>0</td>
</tr>
<tr>
<td>P22525</td>
<td>ycbB</td>
<td>Probable l,d-transpeptidase YcbB</td>
<td>67</td>
<td>0</td>
</tr>
<tr>
<td>P76115</td>
<td>yncD</td>
<td>Probable TonB-dependent receptor YncD</td>
<td>77</td>
<td>0</td>
</tr>
<tr>
<td>P0A7R5</td>
<td>rpsl</td>
<td>30S ribosomal protein S10</td>
<td>12</td>
<td>3</td>
</tr>
<tr>
<td>P0A4715</td>
<td>ompX</td>
<td>Outer membrane protein X</td>
<td>19</td>
<td>150</td>
</tr>
<tr>
<td>P0A040</td>
<td>mipA</td>
<td>MlaA-interacting protein</td>
<td>28</td>
<td>16</td>
</tr>
<tr>
<td>P06996</td>
<td>ompC</td>
<td>Outer membrane protein C</td>
<td>40</td>
<td>364</td>
</tr>
</tbody>
</table>

<sup>a</sup> Fold change in the OMVs containing either HbpD-Δd1 or HbpD-ESAT6 compared to the empty vector (EV) control OMVs.
Display of M. tuberculosis antigens at the surface of Salmonella OMVs. To investigate whether Hbp derivatives are targeted to Salmonella OMVs, Hbp-DΔd1 and Hbp-antigen fusions were produced in SL3261 tolRA, and crude OMVs were isolated as described for the E. coli OMVs. As shown by protein staining upon SDS-PAGE and immunoblotting, the various chimeras, similar to OmpF/C and OmpA, were detected in the OMV preparations. As observed in E. coli, OMV production was slightly affected upon expression of the most complex constructs, HbpD-Ag85BC and HbpD-Ag85BCΔESAT6-Rv2660c, as judged by the levels of porins detected (Fig. 5B, lanes 4 and 5). Importantly, treatment of intact OMVs with proteinase K demonstrated that all the chimeras were accessible at the surface of the Salmonella OMVs (Fig. 5D). Periplasmic OmpA was not degraded unless the vesicles were lysed by treatment with Triton X-100, indicating that the vesicles remained intact during the treatment. The band corresponding to OmpF/C was unaffected by the protease treatment, indicating that, in contrast to E. coli, the external loops of these proteins are not accessible at the surface of the Salmonella OMVs. In conclusion, efficient surface display of multiple heterologous proteins at the surface of Salmonella OMVs was achieved by combining the Hbp display platform with the newly constructed S. Typhimurium SL3261 ΔtolRA mutant strain.

Display of epitopes from C. trachomatis MOMP on Salmonella OMVs. The immunodominant major outer membrane protein of C. trachomatis is considered an attractive target for development of a subunit vaccine against chlamydial disease. This cysteine-rich protein inserts into the chlamydial OM in a β-barrel conformation, but attempts at recombinant MOMP production typically fail due to misfolding and aggregation (52). To avoid these problems, we decided to express immunogenic fragments of MOMP as fusions to Hbp. In a single Hbp carrier molecule, d1 and d2 were replaced by fragments corresponding to aa 266 to 350 and aa 155 to 190 of MOMP, respectively (Jong et al., unpublished). These fragments, respectively, encode the surface-exposed variable sequences (VS) VS4 and VS2 of MOMP, which contain structural B cell epitopes (53), and adjacent intracellular sequences that are enriched in conserved CD4+ and CD8+ T cell epitopes (54). Upon production in S. Typhimurium SL3261 ΔtolRA, the HbpD-MOMPIV-MOMPII chimera was directed to
the surface of the derived OMVs and were, as such, accessible to added proteinase K (Fig. 6). Strikingly, the efficiency of display was similar to that of HbpD-Δd1 (Fig. 6), underscoring the versatility of the Hbp platform.

**Efficient processing and MHC class II-restricted presentation of Ag85B displayed at the surface of Salmonella OMVs.** The mycobacterial proteins Ag85B and ESAT6 are potent T cell antigens (55). To determine whether antigen delivery by S. Typhimurium OMVs leads to proper processing and presentation of the exogenously inserted T cell epitopes, we took an in vitro approach. OMVs with surface-exposed Hbp chimeras were incubated with murine BMDCs to allow antigen uptake and processing. After removal of external OMVs by extensive washing, the BMDCs were cocultured with DE10 T cell hybridoma cells that specifically recognize an Ag85A241–260 peptide that is restricted by the murine major histocompatibility complex (MHC) class II molecule I-A^b (50). Importantly, the DE10 cells also recognize a highly similar I-A^b-restricted peptide in Ag85B, i.e., Ag85B_281–300. Production of IL-2 showed that the DE10 hybridoma cells recognized appropriate histocompatible BMDCs that had been incubated with OMVs exposing HbpD-Ag85B_281–300 and HbpD-ESAT6 or the empty vector control (Fig. 7). Production of IL-2 in response to the synthetic Ag85A241–260 peptide, but not to an unrelated peptide control, confirmed the specificity of the DE10 hybridoma cells (data not shown). In addition, incubation of the hybridoma cells with the purified HbpD-Ag85B_281–300 fusion protein and increasing concentrations of OMVs confirmed that the antigen-specific IL-2 production was not affected by toxicity of the OMVs toward the BMDCs or the hybridoma cells (data not shown). These data show that delivery of the S. Typhimurium OMVs to DCs in vitro leads to correct and efficient processing and presentation of an immunodominant Ag85B CD4^+ T cell epitope that can be recognized by *M. tuberculosis*-specific T cells.

**DISCUSSION**

This work demonstrates that the Hbp autotransporter platform enables efficient targeting of heterologous proteins to the surface of *E. coli* and *Salmonella* OMVs. Targeting of heterologous polypeptides to *E. coli* or *Salmonella* OMVs has previously been studied in detail upon fusion to the N and C termini of the vesicle-associated toxin ClyA (21) and to the β-barrel of the autotransporter AIDA (22). However, detection of Hbp chimeras at the Coomassie level highlights the remarkable efficiency of the Hbp system compared to these previous approaches. Despite the fact that it was not enriched in the OMVs compared to the *E. coli* OM, Hbp was one of the major proteins detected in both *E. coli* and *Salmonella* OMVs. Furthermore, and in contrast to previous work, the side domain replacement strategy allows incorporation of multiple heterologous sequences in the same display module, demonstrating for the first time the simultaneous display of multiple antigens at the OMV surface (Fig. 1B).

Importantly, overexpression of Hbp had no major influence on the OMVs as no major changes in the size or morphology were detected, and only little variation was observed in the protein...
composition of the OMVs isolated from the *E. coli* strain producing Hbp compared to those from the control strain. The most striking difference was the presence of GroEL and PDH-E1 in OMVs carrying Hbp (derivatives). This was somewhat surprising, considering that cytoplasmic and IM proteins are generally not present or are present only at very low levels in OMVs (4, 56). However, GroEL and members of the PDH complex have frequently been detected by proteomics in OMV preparations (57–60). Our analyses showed that GroEL and PDH-E1 were loosely associated with the OMV surface. Furthermore, OMV-associated GroEL was detected as an ~700-kDa complex upon blue native PAGE (data not shown), consistent with its cytoplasmic tetradecameric form (61). Therefore, and given their frequent association with OMVs and bacterial surfaces (57–60, 62), it is likely that GroEL and PDH-E1 leak from cells under stress conditions and reassociate with bacterial outer membranes or vesicles. Indeed, mild stress could be triggered by the overexpression of Hbp, a notion that is supported by the concomitant upregulation of the outer membrane lipoprotein OsmB, which is encoded by a multistress-responsive gene (63), and of OmpX, which is also known to respond to stress conditions (64). Finally, it should be noted that the overall levels of OMV production appeared slightly reduced upon expression of Hbp fused to three or four antigenic fragments. Although no striking differences were observed by general protein staining, we cannot rule out additional effects on the composition of the OMVs upon expression of more complex fusion proteins.

The robust display of three mycobacterial antigens, individually or simultaneously, at the surface of *E. coli* and *Salmonella* vesicles demonstrates the versatility of the Hbp platform. This versatility is further underscored using a fusion between Hbp and two immunogenic fragments of the *C. trachomatis* MOMP. This chimera was displayed at the surface of *Salmonella* OMVs with an outstanding efficiency, offering an alternative approach to the notoriously difficult recombinant production of MOMP. The advantage of combining multiple antigens in the same vaccine was previously described as immunization with an Ag85B-ESAT6-Rv2660c fusion protein promoted stronger immune responses and better protection against *M. tuberculosis* challenge in mice than vaccines based on the individual antigens (65). Efficient processing and presentation of OMV-associated Ag85B to the MHC class II pathway upon delivery to dendritic cells further highlight the applicability of our system for OMV vaccine development. Indeed, our preliminary data indicate that mice immunized intranasally with OMVs displaying HbpD-Ag85B$_{C_{1-N}}$-ESAT6-Rv2660c produce pulmonary vaccine-induced CD4$^+$ T cell responses, further emphasizing the potential of our approach for the development of recombinant OMV vaccines (Long et al., unpublished).

**ACKNOWLEDGMENTS**

The research leading to these results has received funding from the European Union’s Seventh Framework Programme (FP7/2007-2013) under grant agreement number 280873 ADITEC. In addition, W.S.P.J. was supported by a grant from the Dutch Technology Foundation, and Z.S. was supported by a Mosaic Grant from the Netherlands Organization for Scientific Research.

We thank G. Koningstein and R. C. van der Schors for technical assistance with the mass spectrometry, J. Tommassen, T. Silhavy, I. Rosenkrands, and P. Andersen for providing antiserum, and S. Wagner for helpful discussions.

M.H.D.-S., C.M.T.H.-J., W.S.P.J., and J.L. are involved in Abera Bioscience AB, which aims to exploit the Hbp platform for vaccine development. D.V. and J.-W.D.G. are involved in Xbrane Bioscience AB. Abera Bioscience AB and Xbrane Bioscience AB are both part of Serendipity Innovations.

**REFERENCES**


